Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery (CABG)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30326
- Emory University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Males or females between the ages of 18 and 80 years undergoing CABG +/- valve surgery.
- Post surgical hyperglycemia (BG > 140 mg/dl).
- Patients with and without a history of type 2 diabetes
Exclusion Criteria:
- Patients requiring combination CABG with additional procedures such aorta replacement.
- Patients with severely impaired renal function (serum creatinine ≥3.0 mg/dl or GFR < 30 ml/min) or clinically significant hepatic failure.
- Subjects with acute hyperglycemic crises such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.
- Moribund patients and those at imminent risk of death (brain death or cardiac standstill).
- Patients or next-to-kin with mental condition rendering the subject or family member unable to understand the nature, scope, and possible consequences of the study.
- Female subjects who are pregnant or breast-feeding at time of enrollment into the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Intensive insulin treatment
Intensive insulin treatment (BG target: 100-140 mg/dL)
|
Titration of the IV insulin rate for glucose goal 100-140 mg/dL
|
|
Aktiver Komparator: Conventional insulin treatment
Conventional insulin treatment (BG target: 141-180 mg/dl)
|
Titration of the IV insulin rate for glucose goal 141-180 mg/dl
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Subjects That Were Diagnosed for Peri-operative Complications
Zeitfenster: Within 6 months of hospitalization
|
Number of participants that presented at least 1 complications including sternal wound infection, bacteremia, acute renal failure, respiratory failure, and major cardiovascular events (MACE) during the current hospitalization and up to 6 months after hospitalization
|
Within 6 months of hospitalization
|
|
Hospital Mortality
Zeitfenster: average 1 month during the hospitalization
|
Mortality is defined as death occurring during admission, either during ICU or after transition to non-ICU admission.
|
average 1 month during the hospitalization
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Glycemic Control
Zeitfenster: average 1 month during the hospitalization
|
|
average 1 month during the hospitalization
|
|
Major Cardiovascular Events
Zeitfenster: average 1 month during the hospitalization
|
|
average 1 month during the hospitalization
|
|
Acute Renal Failure
Zeitfenster: average 1 month during the hospitalization
|
new-onset abnormal renal function: serum creatinine > 2.0 mg/dL or an increment level > 50% from baseline
|
average 1 month during the hospitalization
|
|
Respiratory Failure, Defined as PaO2 Value < 60 mm Hg While Breathing Air or a PaCO2 > 50 mm Hg.
Zeitfenster: average 1 month during the hospitalization
|
Respiratory failure, defined as PaO2 value < 60 mm Hg while breathing air or a PaCO2 > 50 mm Hg.
|
average 1 month during the hospitalization
|
|
ICU and Hospital Length of Stay, and ICU Readmissions
Zeitfenster: average 1 month during the hospitalization
|
ICU and hospital length of stay, and ICU readmissions
|
average 1 month during the hospitalization
|
|
Surgical Wound Infection
Zeitfenster: average 1 month during the hospitalization
|
superficial and deep sternal wound infection
|
average 1 month during the hospitalization
|
|
Pneumonia (CDC Criteria)
Zeitfenster: average 1 month during the hospitalization
|
Pneumonia (CDC criteria)
|
average 1 month during the hospitalization
|
|
Cerebrovascular Events
Zeitfenster: average 1 month during the hospitalization
|
permanent stroke and reversible ischemic neurologic deficit.
|
average 1 month during the hospitalization
|
|
Duration of Ventilatory Support and ICU Readmission
Zeitfenster: average 1 month during the hospitalization
|
Duration of ventilatory support and ICU readmission
|
average 1 month during the hospitalization
|
|
Thirty Day Mortality
Zeitfenster: within 30 days of discharge
|
Thirty day mortality
|
within 30 days of discharge
|
|
Number of Hospital Readmissions and Emergency Room Visits
Zeitfenster: Within 30 days after discharge
|
Number of hospital readmissions and emergency room visits
|
Within 30 days after discharge
|
|
Incidence of Organ Failures Assessed by the Daily SOFA Score
Zeitfenster: average 1 month during the hospitalization
|
Incidence of organ failures assessed by the daily SOFA score
|
average 1 month during the hospitalization
|
|
Measures of Inflammation
Zeitfenster: average 1 month during the hospitalization
|
Measures of inflammation (C-reactive protein, TNF-alpha; IL-6) and oxidative stress markers
|
average 1 month during the hospitalization
|
|
Major Cardiovascular Events
Zeitfenster: within 3 months after discharge
|
|
within 3 months after discharge
|
|
Surgical Wound Infection
Zeitfenster: within 3 months after discharge
|
Superficial and deep sternal wound infection
|
within 3 months after discharge
|
|
Pneumonia (CDC Criteria)
Zeitfenster: Within 3 months after discharge
|
Pneumonia (CDC criteria)
|
Within 3 months after discharge
|
|
Cerebrovascular Events
Zeitfenster: within 3 months after discharge
|
permanent stroke and reversible ischemic neurologic deficit
|
within 3 months after discharge
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Guillermo E Umpierrez, MD, Emory University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IRB00048356
- 00048356-2010 (Andere Kennung: Other)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .